🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ciro Celsa

Hammersmith Hospital

ORCID: 0000-0002-5662-2162

Also affiliated with Department of Health, Imperial College London, University of Palermo

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis”.

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

The Lancet Oncology(2024)10.1016/s1470-2045(24)00457-1

N/A

1.7DataRank · unranked

70 citations

Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Vincent Yip +18 more

First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

Liver Cancer(2021)10.1159/000520278

N/A

0DataRank · unranked

50 citations

María Reig, Ciro Celsa, Ferràn Torres, Salvatore Battaglia, Marco Enea +9 more

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

JHEP Reports(2025)10.1016/j.jhepr.2025.101685

N/A

0DataRank · unranked

2 citations

Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li +36 more